Prognostic value of ATN Alzheimer biomarkers: 60‐month follow‐up results from the Argentine Alzheimer's Disease Neuroimaging Initiative

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring

Silvia Vázquez¹  Lucia Crivelli²  Gabriela Cohen²  Jorge Campos²  Federico E. Nahas²  Ismael Calandri²  María Julieta Russo²  María Florencia Clarens²  Fernanda Tapajóz²  Maria Eugenia Martín²  Ricardo F. Allegri²  Patricio Chrem Méndez²  Lucia Pertierra²  Gustavo Sevlever³  Ezequiel Surace³ 

[1] Center of Molecular Neuroimaging Instituto de Investigaciones Neurológicas FLENI Buenos Aires Argentina;Department of Cognitive Neurology Neuropsychiatry and Neuropsychology, Instituto de Investigaciones Neurológicas FLENI Buenos Aires Argentina;Department of Molecular Biology and Neuropathology Instituto de Investigaciones Neurológicas FLENI Buenos Aires Argentina;

关键词: Alzheimer's disease;    biomarkers;    amyloid;    tau;    neurodegeneration;    classification;   

DOI  :  10.1002/dad2.12026

来源: DOAJ

【 摘 要 】

Abstract Purpose To describe results of the Amyloid, Tau, Neurodegeneration (ATN) research framework classification in the Argentine‐Alzheimer's Disease Neuroimaging Initiative (arg‐ADNI) cohort. Methods Twenty‐three patients with mild cognitive impairment (MCI), 12 dementia of Alzheimer's type (DAT), and 14 normal controls were studied following the ADNI2 protocol. Patients were categorized according to presence or absence of the biomarkers for amyloid beta (Aβ; A: amyloid positron emission tomography [PET] scan or cerebrospinal fluid [CSF] Aβ42), tau (T: CSF phosphorylated‐tau), and neurodegeneration (N: CSF total‐tau, fluorodeoxyglucose [FDG]‐PET scan, or structural magnetic resonance imaging [MRI] scan). Results A+T+N+ biomarker profile was identified at baseline in 91% of mild dementia patients, 20% of early MCI patients, 46% of late MCI patients, and 14% of control subjects. Suspected non‐AD pathophysiology (SNAP, A‐T‐N+) was found in 8% of mild dementia, 20% of early MCI, 15% of late MCI, and 7% of control subjects. Conversion rates to dementia after 5‐year follow‐up were 85% in A+T+N+ MCI patients and 50% in A‐T‐N+ patients. Conclusions We present initial 5‐year follow‐up results of a regional ADNI based on AD biomarkers and the ATN classification.

【 授权许可】

Unknown